About
Profile
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
LYRA
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Lyra Therapeutics appoints chief technology officer
- Lyra Therapeutics GAAP EPS of -$0.40 beats by $0.04, revenue of $0.36M beats by $0.16M
- Lyra Therapeutics GAAP EPS of -$0.43, revenue of $0.4M
- Lyra Therapeutics appoints Nieman as Chief Medical Officer
- Lyra Therapeutics initiated with an overweight rating at Cantor Fitzgerald; sees 147% upside
- Lyra Therapeutics GAAP EPS of -$0.54 beats by $0.38, revenue of $5.37M beats by $4.12M
- Lyra Therapeutics to raise $100.5M via private placement of securities
- Lyra Therapeutics GAAP EPS of -$3.35 misses by $0.23
- Lyra Therapeutics begins enrollment in phase 3 trial of LYR-210 for rhinosinusitis
- Lyra Therapeutics begins phase 3 trial of rhinosinusitis therapy LYR-210
- Lyra Therapeutics EPS misses by $0.12, misses on revenue
- Lyra rhinosinusitis candidate LYR-210 shows durable response after treatment removed
- Lyra Therapeutics posts results from mid-stage LYR-210 chronic rhinosinusitis study
- Lyra Therapeutics appoints Jason Cavalier as CFO
- Lyra Therapeutics EPS misses by $0.26
- Lyra Therapeutics pops 8% on positive LYR-210 results in chronic rhinosinusitis
- LYRA, WISH, CMTL and ACTG among after-hours movers
- Lyra Therapeutics gets positive outcome from LYR-210 end-of-phase 2 FDA meeting
- Lyra Therapeutics soars 14% on ink licensing deal for LYR-210 in Asia
- Lyra Therapeutics EPS misses by $0.12
| Date | Price | Open | High | Low | Vol | Change | ER | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 8 | 4.300 | 4.760 |
4.760
|
4.210
|
50.59K | -9.86% | ||||
| Mar 7 | 4.770 | 4.690 |
4.910
|
4.531
|
23.77K | 0% | ||||
| Mar 4 | 4.770 | 5.250 |
5.390
|
4.770
|
26.21K | -9.14% | ||||
| Mar 3 | 5.250 | 5.330 |
5.340
|
5.170
|
26.89K | -1.5% | ||||
| Mar 2 | 5.330 | 5.030 |
5.370
|
5.030
|
15.99K | 6.39% | ||||
| Mar 1 | 5.010 | 4.920 |
5.060
|
4.900
|
11.12K | 2.87% | ||||
| Feb 28 | 4.870 | 5.050 |
5.350
|
4.640
|
25.00K | -5.44% | ||||
| Feb 25 | 5.150 | 5.450 |
5.450
|
5.100
|
15.44K | -3.92% | ||||
| Feb 24 | 5.360 | 4.800 |
5.580
|
4.350
|
49.60K | 7.20% | ||||
| Feb 23 | 5.000 | 4.900 |
5.090
|
4.730
|
23.00K | 2.46% | ||||
| Feb 22 | 4.880 | 4.670 |
5.020
|
4.652
|
32.78K | 1.46% | ||||
| Feb 18 | 4.810 | 4.650 |
4.850
|
4.310
|
24.06K | 1.91% | ||||
| Feb 17 | 4.720 | 4.300 |
4.780
|
4.280
|
56.93K | 12.11% | ||||
| Feb 16 | 4.210 | 4.380 |
4.450
|
4.150
|
14.17K | -6.44% | ||||
| Feb 15 | 4.500 | 4.420 |
4.560
|
4.380
|
9.14K | 2.04% | ||||
| Feb 14 | 4.410 | 4.760 |
4.760
|
4.380
|
31.03K | -7.74% | ||||
| Feb 11 | 4.780 | 4.920 |
4.920
|
4.600
|
23.48K | 0% | ||||
| Feb 10 | 4.780 | 4.830 |
4.860
|
4.612
|
10.90K | -0.62% | ||||
| Feb 9 | 4.810 | 4.720 |
4.880
|
4.650
|
11.26K | 4.11% | ||||